It was reported that in-stent occlusion occurred.The subject underwent treatment with eluvia drug-eluting stent on (b)(6) 2022 as a part of the elegance clinical trial.The target lesion was in the right proximal superficial femoral artery (sfa) and right mid sfa with proximal reference vessel diameter of 6 mm and distal reference vessel diameter of 5 mm with lesion length of 200 mm and 100% stenosis and was classified as a tasc ii d lesion.Prior to target lesion treatment with study device, treatment was done using a 2.3 mm non-boston scientific laser followed by placement of 2 mm x 200 mm non-boston scientific bare metal stent.Treatment of target lesion was performed by placement of study device, 6 mm x 80 mm eluvia drug-eluting stent.Following post dilation was performed using 5 mm x 20 mm mustang pta balloon, and the final residual stenosis was noted to be 0%.On (b)(6) 2022, the subject was discharged on clopidogrel.On (b)(6) 2023, during 6 month follow up, ultrasound examination revealed in-stent occlusion of the right sfa.
|